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Abstract
CYP1A1 is one of the main cytochrome P450 enzymes, examined extensively for its capacity to
activate compounds with carcinogenic properties. Continuous exposure to inhalation chemicals
and environmental carcinogens is thought to increase the level of CYP1A1 expression in
extrahepatic tissues, through the aryl hydrocarbon receptor (AhR). Although the latter has long
been recognized as a ligand-induced transcription factor, which is responsible for the xenobiotic
activating pathway of several phase I and phase II metabolizing enzymes, recent evidence suggests
that the AhR is involved in various cell signaling pathways critical to cell cycle regulation and normal
homeostasis. Disregulation of these pathways is implicated in tumor progression. In addition, it is
becoming increasingly evident that CYP1A1 plays an important role in the detoxication of
environmental carcinogens, as well as in the metabolic activation of dietary compounds with cancer
preventative activity. Ultimately the contribution of CYP1A1 to cancer progression or prevention
may depend on the balance of procarcinogen activation/detoxication and dietary natural product
extrahepatic metabolism.
Background
Cytochrome P450s are haem-containing enzymes, which
catalyze various Phase I metabolism reactions, such as C-
, N- and S- oxidation and dealkylation. Cytochrome P450
CYP1A1 is one of the three members of the CYP1 family,
which is found mainly in extrahepatic tissues and partici-
pates in the metabolism of a vast number of xenobiotics,
as well as a small number of endogenous substrates.
Among the different reactions catalyzed by CYP1A1,
hydroxylation at a vacant position of an aromatic ring is
considered to be the hallmark for the initiation of carcino-
genesis, through the formation of highly reactive conver-
sion products that can cause oncogenic mutations in
experimental animals and humans [1,2]. The transcrip-
tional activation of the CYP1A1 gene is mediated by the
binding of environmental pollutants and inhalation
chemicals, notably substrates of the CYP1A1 enzyme, to
the cytosolic receptor AhR and is also mediated by its
translocation to the nucleus and subsequent formation of
a dimer, which interacts with the corresponding xenobi-
otic response elements to activate transcription [3].
Although the xenobiotic-activating pathway of AhR has
been well established for a large number of exogenous lig-
ands, the receptor has been shown to participate in impor-
Published: 16 June 2009
BMC Cancer 2009, 9:187 doi:10.1186/1471-2407-9-187
Received: 23 January 2009
Accepted: 16 June 2009
This article is available from: http://www.biomedcentral.com/1471-2407/9/187
© 2009 Androutsopoulos et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Page 1 of 17
(page number not for citation purposes)
BMC Cancer 2009, 9:187 http://www.biomedcentral.com/1471-2407/9/187tant developmental and cell-regulatory processes, except
foreign compound metabolism. These functions coexist
with the well-characterized toxicological roles of the
receptor. As a result the exact function of CYP1A1 appears
to be a lot more complex than initially thought. Recent in
vivo investigations suggest that CYP1A1 may function as a
carcinogen-detoxication enzyme, whereas the paradoxical
activation of natural dietary compounds with chemopre-
ventative activity provides further insight into the cancer-
protecting role of this enzyme.
In this review, a comprehensive summary of the carcino-
gen-activating role of CYP1A1 is presented, in terms of
substrate specificity, mechanisms of carcinogen activa-
tion, polymorphisms and extrahepatic expression. In
addition, experimental evidence of the interaction of AhR
with various biological pathways, including cell cycle con-
trol, apoptosis, mitogen-activated protein kinases, estro-
gen receptor, glucocorticoid receptor and hypoxia
signaling are addressed. Finally, recent findings with
transgenic animals and in vitro pharmacological evidence,
which point towards a cancer-protecting role of this
enzyme, are presented.
Discussion
Mechanism of activation of procarcinogens by CYP1A1
The deleterious effects of most of the chemical carcino-
gens encountered in the environment are attributed to
metabolic activation by cytochrome P450s to highly reac-
tive conversion products. It has been proven that such
reactive metabolites cause carcinogenicity in experimental
animals and humans whereas their corresponding parent
compounds are chemically inactive [4,5]. Cytochrome
P450 CYP1A1 is one of the more significant P450
enzymes involved in this process. CYP1A1 metabolizes
carcinogens to epoxide intermediates, which are further
activated to diol epoxides by the enzyme epoxide hydro-
lase. The widely accepted paradigm used to demonstrate
this process is the activation of the carcinogen
Benzo[a]pyrene B[a]P.
The metabolic fate of the prototype carcinogen B[a]P was
extensively studied in the mid-1970s in humans [4]. It
was initially thought that the metabolite B[a]P-4,5-epox-
ide, the so-called K-region epoxide, was the ultimate car-
cinogen. However subsequent investigations clearly
demonstrated that B[a]P-7,8-diol-9,10-epoxides, referred
to as bay region epoxides, were highly reactive towards
DNA and thus were classified as the ultimate carcinogenic
metabolites of B[a]P. The exact mechanism of metabolic
activation involves the oxidation of B[a]P to B[a]P-7,8-
oxide, and subsequent hydrolysis to B[a]P-7,8-diol and
the two enantiomers (+)-B[a]P-7,8-diol and (-)-B[a]P-7,8-
diol [6]. A final oxidation of each of these metabolites
produces four diol epoxides, which are highly mutagenic
in Ames Salmonella tester strains and Chinese Hamster V-
79 cells. Additionally the epoxides are denoted as bay
region epoxides due to their ability to cause oncogenic
mutations in specific parts of the DNA [2,6,7]. The metab-
olite (+)-B[a]P-7,8-diol-9,10-epoxide-2 was identified as
the most reactive of the four metabolites in producing
tumors in newborn mice. This metabolite was considered
to be the ultimate carcinogenic conversion product of
B[a]P, because its level of carcinogenicity paralleled that
of B[a]P and (-)-B[a]P-7,8-diol. The structures of B[a]P
and its metabolites are shown in Figure 1A.
With the exception of the hydrolysis step catalyzed by
epoxide hydrolase, the oxidation reactions of B[a]P activa-
tion are promoted by cytochrome P450s. Among the dif-
ferent families, CYP1A1 and CYP1B1 exhibit the highest
catalytic specificity towards B[a]P, as shown by in vitro
experiments with recombinant human P450 enzymes
from E. Coli and Trichoplusia ni cells [6]. Other PAHs have
been investigated for their carcinogenic action and found
to follow the same metabolic activation pattern as B[a]P.
The carcinogen 7,12-Dimethyl benzanthracene (7,12-
DMBA) is oxidized to 7,12-DMBA-3,4-oxide by CYPs, fur-
ther hydrolyzed to its corresponding diol and finally oxi-
dized by CYPs to 7,12-DMBA-3,4-oxide-diol-1,2-epoxide,
which is the ultimate carcinogen (Figure 1B) [6]. Carcino-
genic compounds which fall in the PAH category and are
considered to follow the bay region activation theory
include benz[a]anthracene, benzo[b]fluoranthrene,
benzo[c]phenanthrene, chrysene, benzo[g]chrysene and
5,6-dimethylchrysene. The above-mentioned PAHs
showed selective in vitro metabolism towards human
recombinant CYP1A1 and CYP1B1 and were capable of
inducing DNA-modifying products in the Salmonella
typhimurium NM2009 tester strain [8]. CYP1A1 is further
involved in the activation of aflatoxin B1, a carcinogenic
mycotoxin present in foodstuffs, to its corresponding 8,9-
epoxide in rabbit lung and liver. Further in vivo investiga-
tions have shown that CYP1A1 is involved in B[a]P-
induced carcinogenesis in mice which were positive for
the aryl hydrocarbon receptor AhR (+/+) [6,9,10]. Studies
in this transgenic strain demonstrated an increase in
CYP1A1 expression in both liver and lung, following
treatment of PAHs, such as 5-methylchrysene and 7,12-
DMBA. Hence, the carcinogenic potential of CYP1A1 in
the activation of PAHs has been well documented both in
vitro and in vivo.
CYP1A1 was thought to be uniquely responsible for PAH
activation, until the early 1990s, when CYP1B1 was iden-
tified. Generally the substrate specificities of the two
enzymes towards various pro-carcinogens and pro-muta-
gens are found to be very similar, even though recom-Page 2 of 17
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Metabolic activation of (A) B[a]P and (B) 7,12-DMBA to the carcinogenic metabolites B[a]P-7,8-diol, B[a]P-7,8-diol-9,10-epox-id  nd 7,12-DMBA-3,4-diol, 7,12-DM A-3,4-diol-1,2-epoxide, respectively, by CYP1A1 and epoxide hydrolase [6]Figure 1
Metabolic activation of (A) B[a]P and (B) 7,12-DMBA to the carcinogenic metabolites B[a]P-7,8-diol, B[a]P-
7,8-diol-9,10-epoxide and 7,12-DMBA-3,4-diol, 7,12-DMBA-3,4-diol-1,2-epoxide, respectively, by CYP1A1 and 
epoxide hydrolase [6].
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and stereochemical selectivity for the activation of certain
compounds e.g. DB[a, l]P [6,11,12].
The metabolic activation of heterocyclic amines is also
catalyzed by CYP1A1. PhIP or 2-Amino-1-methyl-6-phe-
nylimidazo[4,5-b]pyridine is the most abundant hetero-
cyclic amine in food, which is a product of cooked meat
and fish. The hydroxylation of PhIP at position N2- is con-
sidered as the initiation step of PhIP-induced carcinogen-
esis [13]. Hydroxylation at position N2, catalyzed by
CYPs, is followed by esterification with N-acetyltrans-
ferase or sulfotransferase to produce the corresponding
esters N2-acetoxy-PhIP and N2-sulfonyloxy-PhIP [14].
These esters form covalent bonds with DNA to yield N2-
(2-deoxyguanosin-8-)-PhIP, and with proteins to the
metabolite 5-hydroxy-PhIP, a degradation product occur-
ring spontaneously. The chemical structures of PhIP and
metabolites are shown in Figure 2.
PhIP-DNA adducts have been detected in various tissues
of rats and mice, as well as in the colon of humans [15].
Although CYP1A2 is a significant isoform involved in
PhIP activation in the liver, CYP1A1 plays an equally
important role in this process in extrahepatic tissues, such
as the lung. Early studies with knockout mice have shown
that PhIP-DNA adducts were detected in extrahepatic tis-
sues of Cyp1a2 null mice, implying a role of CYP1A1 in
PhIP metabolic activation [16]. A recent study by
Gonzalez demonstrated that the N2-hydroxylation of
PhIP was increased almost 2-fold in lung homogenates of
Cyp1a2 null mice, compared to wild-type mice whereas it
reached minimal levels in Cyp1a1 null mice [13]. In addi-
tion, PhIP-DNA adducts were significantly higher in lung
samples from Cyp1a2 null strains, as opposed to Cyp1a1
null mice and almost equivalent with the amount present
in wild-type mice [13]. In the humanized CYP1A2
(CYP1A2_CYP1A1 Cyp1a2 null) transgenic strain it was
shown that N2-hydroxylation was favored over 4'-hydrox-
ylation of PhIP [14]. This implies that in humans oxida-
tion of the exocyclic amino group (N2-hydroxylation) is
the major route of metabolism, followed by glucuronida-
tion, whereas in rats and rodents 4' hydroxylation to 4'-
hydroxy PhIP followed by phase II conjugation is the pre-
dominant metabolic pathway, which has been shown to
be associated with detoxication rather than metabolic
activation. However, the humanized CYP1A1
(CYP1A2_CYP1A1 Cyp1a1 null) strain was not examined
in this study, in terms of PhIP metabolism [14].
CYP1A1 has also been shown to be involved in the activa-
tion of tobacco-related N-nitrosamines, such as NNK,
along with CYP1A2 and CYP2A6 [17]. Such compounds
induce cancer in experimental animals and their activa-
tion step requires hydroxylation of the α-position carbon
atom of N-nitroso group, a reaction catalyzed by CYPs
[18].
CYP1A1 induction is mediated by the AhR, a receptor 
involved in various biological processes
The induction of CYP1A1 expression is mediated through
a specific cytosolic receptor, the Aryl hydrocarbon recep-
tor or AhR. AhR exists as part of a cytosolic protein com-
plex, which consists of two Hsp-90 heat-shock proteins, a
Hsp-90-interacting co-chaperone p23 and an immu-
nophillin-like protein XAP2 or AIP [19]. In the presence of
an exogenous ligand such as B[a]P or the industrial
byproduct 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)
the receptor complex translocates to the nucleus, where it
heterodimerizes with another protein, the aryl hydrocar-
bon nuclear translocator or ARNT (Figure 3). This het-
erodimer binds to consensus regulatory sequences termed
AhREs (Aryl hydrocarbon response elements) XREs
(Xenobiotic response elements) or DREs (Dioxin
response elements), located in the promoter region of
AhR target genes such as CYP1A1 and CYP1A2 and initi-
ates their transcription by recruiting RNA polymerase II
(Figure 3) [19]. The transcription of CYP1A1 is inhibited
by the AhR-related factor Aryl hydrocarbon receptor
repressor or AhRR, which localizes in the nucleus in the
form of a dimeric protein along with ARNT (Figure 3). The
AhRR/ARNT heterodimer acts as a repressor both by stop-
ping transcription initiated at the XREs and by competing
with AhR for heterodimer formation with ARNT. All AhR,
ARNT and AhRR are members of the bHLH (basic helix-
loop-helix) PAS (Per-ARNT-Sim) family of proteins. The
bHLH motif is shared by other transcription factors such
as Myc and MyoD and is the protein part essential for
DNA binding of the AhR complex [20]. Heterodimerisa-
tion of AhR/ARNT is facilitated by interactions between
bHLP and PAS domains. Further interactions of the AhR/
ARNT heterodimer with transcription factors such as Sp1
and NF-1 are essential to enhance the expression of the
CYP1A1 gene. Other proteins which possess HAT (His-
tone Acetyltrasnferase) activity and act as co-activators
include SRC-1 (Steroid receptor co-activator), NcoA2
(Nuclear co-activator 2), p/CIP and p300. SRC-1, NcoA2
and p/CIP have been shown to associate with the mouse
Cyp1a1 enhancer region and to enhance XRE-driven
reporter gene transcription [20-22]. Using ChIP analysis,
Hatkinson has shown that co-activators such as p300 and
p/CIP bind to the enhancer but not to the promoter
region of the mouse Cyp1a1 gene, following TCDD treat-
ment, whereas RNA polymerase II binds only to the pro-
moter and not to the enhancer region of the same gene
[23]. In contrast, Puga and co-workers found that p300
binds both to the enhancer and promoter following B[a]P
treatment [24]. It is believed that co-activator recruitment,
enhances the gene transcription of CYP1A1 and aids in the
binding of Pol II and transcription factors to the CYP1A1Page 4 of 17
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Metabolic activation of PhIP to the carcinogenic metabolite N2-hydroxy PhIP by CYP1A enzymes and epoxide hydrolase [14]Figure 2
Metabolic activation of PhIP to the carcinogenic metabolite N2-hydroxy PhIP by CYP1A enzymes and epoxide 
hydrolase [14].
BMC Cancer 2009, 9:187 http://www.biomedcentral.com/1471-2407/9/187promoter, thus facilitating gene transcription. Neverthe-
less, it still remains unclear whether participation of co-
activator proteins is the same in all tissues, where CYP1A1
is inducible. Further investigation is required for a conclu-
sive report on the molecular events involving co-activator,
transcription factor and Pol II recruitment in the transac-
tivation of the CYP1A1 gene.
This proposed mechanism of CYP1A1 induction also
applies to certain Phase II xenobiotic metabolizing
enzymes, such as NQO1, UGT1A6, ALDH3A1 and several
glutathione S-transferases, and was initially thought to be
the primary role of AhR in the mid 1990s [3]. However,
recent discoveries have illuminated a wider function of
AhR, than initially thought. It is now generally accepted
that the receptor is involved in physiological functions
beyond xenobiotic metabolism, such as regulation of cell
growth, apoptosis, hypoxia signaling, cell adhesion and
matrix metabolism [19,25,26]. Based on accumulating
experimental data we broadly categorized the AhR in
AhR ligand-mediated activation of phase I and II metabolizing enzyme genesFigure 3
AhR ligand-mediated activation of phase I and II metabolizing enzyme genes. The diagram represents a basic model 
of the molecular events following the entry of an AhR ligand, such as TCDD, in the cell. Upon ligand binding the AhR complex 
dissociates with XAP2, p23 and HSP90 proteins and translocates to the nucleus. Nuclear import is inhibited by phosphoryla-
tion reactions of either Ser-12 or Ser-36 residues of the Nuclear localization signal (NLS), while phosphorylation of phosphoty-
rosine residues in the carboxy terminal of the AhR is required for the formation of a functional AhR/ARNT complex [19]. 
Binding of the AhR/ARNT complex to XRE is inhibited by the ARNT/AhRR dimer. Initiation of the transcription of genes 
encoding for phase I and phase II metabolizing enzymes occurs via the interaction of several transcription factors such as Sp1 
and co-activators such as p-300 and p/CIP, which eventually leads to binding with TBP (TATA binding protein) and subsequent 
recruitment of RNA polymerase II [20-22]. There is a great number of other transcription factors, co-activators and general 
transcription factors (GTFs) involved in this process, which are not shown for clarity.Page 6 of 17
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xenobiotic signaling pathway, which usually requires an
exogenous ligand for activation and results in the induc-
tion of several Phase I and Phase II metabolizing genes. A
second network of pathways involves the interaction of
the AhR with various cell-signaling proteins, such as Rb
and E2F in the presence or absence of an inducer. The
third pathway is the intrinsic AhR pathway, which
remains elusive, in terms of exact mechanism of action
and is thought to be dependent on an endogenous ligand
and play key roles in important physiological and devel-
opmental processes. The above mentioned pathways are
likely to interact with one another, proving that the exact
function of the receptor is a lot more complex, than ini-
tially thought.
Interaction of AhR with protein kinase C and tyrosine 
kinases
The first line of evidence, which supports a positive inter-
action between AhR and PKC is derived from early studies
in mice, where it was shown that the inhibition of PKC
blocks ligand-activated DNA binding of AhR/ARNT het-
erodimers, leading to a decreased Cyp1 gene expression
[27,28]. Previous studies have provided further insight to
a more complex signaling mechanism by which the activ-
ity of the AhR complex is regulated by PKC. AhR contains
a nuclear localization signal (NLS), composed of the
amino acid residues 13–16 and 37–39, and a nuclear
export signal (NES) [29]. Ikuta showed in 2004 that the
ligand-dependent nuclear input of AhR is inhibited by
phosphorylation of either Ser12 or Ser36 by PKC. The
replacement of Serine residues with Alanine does not
affect nuclear translocation, whereas replacement with
Asp retains the mutant AhR in the cytoplasm. PKC, how-
ever, does not appear to be directly involved in AhR-medi-
ated transcription, as Ala and Asp replacement mutants in
in vitro luciferase reporter assays had much lower tran-
scriptional activity than the wild type. By analogy to the
regulation of NLS, phosphorylation of the Ser 68 residue
by p38 of NES, has been demonstrated to activate the
export of the receptor from the nucleus [30]. In addition,
phosphorylation at the tyrosine residues of the carboxy
terminal half of AhR is required for the formation of the
functional AhR/ARNT heterodimer, whereas phosphor-
ylation of the Serine residues of HSP90 proteins modu-
lates the formation of a functional cytosolic AhR complex
[19]. Thus, it appears that the induction of CYP1A1 is
tightly regulated by phosphorylation reactions occurring
at the AhR functional domains.
Cross-talk of MAPK kinases with AhR
MAPK kinases are serine threonine kinases, involved in
inflammatory responses, apoptosis, cell growth and fur-
ther mitogenic and developmental events. It is becoming
increasingly accepted that the AhR pathway is linked to an
extent with MAPKs. Prototype AhR activators have been
shown to have a positive effect on the activation of several
MAPKs. For example, the TCDD-induced modulation of
epithelial morphology causes the activation of JNK [31].
These dioxin-mediated effects can be mimicked by a con-
stitutive expression of AhR. In addition, ablation of JNK2
and ERK affects TCDD-induced CYP1A1 transactivation
by decreasing its expression in mouse thymus and testis
[32]. It has been further noted that CYP1A1 and CYP1B1
mRNA and protein expression can be induced in human
keratinocytes, after UV exposure. It has been proposed
that thryptophan-derived photoreactive products, which
are weak agonists of AhR are responsible for this effect,
even though the contribution of JNK and p38 activation,
which occurs under UV radiation, cannot be entirely dis-
missed. The induction of ERK and JNK was also noted in
A-549 human lung carcinoma and Hepa-1 mouse
hepatoma cells, which possess a functional AhR battery,
following treatment of TCDD or B[a]P [33,34]. In addi-
tion, the interaction of AhR with ERK, appears to be criti-
cally linked to the function of the receptor, as ERK
inhibitors were shown to prolong TCDD-induced AhR
degradation. More importantly it has been shown in
Hepa1c1c7 cells that ERK is physically associated with
AhR, and that the overexpression of ERK1 promoted AhR
degradation, suggesting that ERK plays an important role
in the proteolysis of the receptor [35]. Moreover, constitu-
tively active MEK1, which is the MAPKK upstream of ERK
1/2, increased the TCDD-mediated induction of CYP1A1
via the AhR [33]. Based on previous investigations regard-
ing cross-talk of the MAPKs with AhR, it can be concluded
that exogenous ligands of the receptor contribute to the
upregulation of several MAPKs, which in turn exert a pos-
itive interaction on the translocation of the AhR complex
to the nucleus and subsequently the activation of several
Phase I and Phase II metabolizing genes, including
CYP1A1.
Role of AhR in cell cycle progression
The effects of AhR in cell cycle progression are distinct,
depending on the presence or absence of an exogenous
ligand. Although in the absence of a ligand AhR promotes
progression of the cell cycle as shown in mouse hepatoma
Hepa1c1c7, AhR null MEF cells and HepG2 human
hepatoma cells transfected with AhR siRNA, accumulating
data strongly suggests that TCDD inhibits cell prolifera-
tion [36-40]. TCDD induces cell cycle arrest in normal
cells and inhibits the growth of MCF-7 breast adenocarci-
noma cells, stimulated by 17-β oestradiol, as well as pro-
liferation of the fish hepatocellular carcinoma PLHC-1
cell line and the androgen-induced LNCap human pros-
tate cancer cell line [41-43]. A delayed G1 to S phase tran-
sition has been noted in 5L hepatoma cell cultures,
following TCDD treatment, which was attributed to
induction of the p27Kip1 cell cycle inhibitor. CYP1A1Page 7 of 17
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the length of AhR activation as 5L cells that were treated
simultaneously with serum and the CYP1A1 suicide sub-
strate 1-PP showed prolonged AhR activation and p27Kip1
induction, similar to that of TCDD alone [44,45]. Addi-
tional data have shown that AhR blocks the phosphoryla-
tion of RB in G1 by forming complexes with its
hypophosphorylated form [46]. This interaction is sup-
ported by two AhR domains, one found in the cyclin D
LXCXE motif and the other present within the transactiva-
tion domain of the receptor [47]. The end result is the
repression of E2F-dependent gene expression, which
involves proteins such as cyclin E, CDK2, DNA polymer-
ase α and DHFR and the repression of RB-target genes, as
well as the exclusion of co-activator proteins from RB-pro-
moters, suggesting an RB-corepressor function of the AhR
[48]. In contrast to these findings, investigations in stably
integrated AhR variants in fibroblasts from AhR null mice,
show that AhR+/+ proliferate faster than AhR-/- fibroblasts,
while the addition of TCDD did not change the rate of
proliferation [49]. This indicates a ligand-independent
AhR regulation of the cell cycle. In AhR-/- cells cyclin-CDK
complexes were downregulated whereas the expression of
cell cycle inhibitors was upregulated [49]. In addition, a
recent study has shown that constitutively active AhR con-
tributes to basal CYP1B1 but not CYP1A1 mRNA levels in
immortalized and malignant mammary cell lines,
whereas AhR hyperactivation by TCDD activates both
genes, which implies a contribution of AhR and CYP1B1
prior to tumor formation [50]. These two contradictory
bodies of evidence imply the wider function of AhR in the
presence and absence of a ligand. It is also important to
note that the precise function of AhR in cell proliferation
may be different among the various cell or tissue types
[19].
Interaction of AhR with other pathways
AhR has been shown to interact with the glucocorticoid
receptor (GR) both in vitro and in vivo [51-54]. The gluco-
corticoid dexamethasone has been shown to enhance
TCDD-induced expression of CYP1A1, in a rat hepatoma
and fish hepatocellular carcinoma cell lines [54,55].
Although many studies have been conducted in rodent
models in terms of AhR and GR cross-talk, little informa-
tion is available for humans [51-53]. Recent evidence
from studies in HepG2 cells and primary cultures of
human hepatocytes has shown that dexamethasone
reduces both basal and inducible CYP1A1 EROD activity
[56,57]. Furthermore, dexamethasone was shown to have
direct effects on the modulation of TCDD-induced tran-
scriptional activation as well as the degradation of AhR in
HepG2 cells. In contrast, experiments conducted in
human hepatocytes experiments with the glucocorticoid
receptor antagonist RU486 in the presence and absence of
dexamethasone, showed a downregulation of basal and
TCDD-induced AhR and GR mRNAs and AhR protein
[56,57]. These findings show that dexamethasone con-
trols CYP1A1 expression in human hepatocytes and
HepG2 cells through interactive regulatory cross-talk
between GR and AhR receptors.
Cross-talk of AhR and ARNT with the oestrogen receptor
α (ERα) has also been established in a number of different
systems [58,59]. TCDD does not bind to ERα, but it inhib-
its ERα signaling. More importantly ERα plays a signifi-
cant role in modulating AhR activity, as it has been
reported by in vitro and in vivo studies that treatment of
TCDD and E2 results in an increased induction of
CYP1A1, compared to TCDD treatment alone [60,61].
ERα has a direct interaction with the CYP1A1 promoter,
suggesting that it acts as a co-regulator of AhR-mediated
transcriptional activation [60]. In human bronchial epi-
thelial cells ERα increased the basal mRNA levels of
CYP1B1 and the inducible protein levels of CYP1A1, thus
regulating the expression of these genes at a transcrip-
tional and a translational level, respectively [62]. The
interaction of ERβ with AhR and ARNT has also been sug-
gested [63]. Such literature implies that both ERα and ERβ
can regulate the expression of carcinogen-metabolizing
genes such as CYP1A1.
The dimerisation partner of AhR, ARNT is also called HIF-
1β (Hypoxia inducible factor 1β). In addition to binding
with AhR, ARNT dimerises with the protein HIF-1α to
form HIF-1 (Hypoxia inducible factor). HIF-1α is also a
member of basic helix-loop-helix (bHLH) Per-ARNT-Sim
(PAS) proteins [64,65]. Upon the formation of HIF-1, the
induction of transcription of hypoxia-related genes such
as VEGF and PDGF is initiated, by the binding of HIF-1α
to hypoxia response element (HREs) sequences [66].
Since the sequestration of ARNT is challenged by both
AhR and HIF-1α, certain studies have supported the
notion that the limiting cellular factor ARNT is shared
between two pathways [67-69]. In this sense, reciprocal
crosstalk between hypoxia and dioxin signal transduction
pathways has been demonstrated to occur in vitro and in
vivo [67]. Hypoxia may downregulate the expression of
AhR, and subsequently CYP1A1, as dioxin upregulates the
expression of erythropoietin via AhR-ARNT binding to
DREs upstream of the transcriptional start site [67].
Increased oxygen supplementation, or hyperoxia has been
shown to significantly induce CYP1A1 mRNA, protein
and activity in human lung cell lines by means of an AhR-
dependent mechanism [70].
CYP1A1 expression
CYP1A1 is believed to be the primary extrahepatic enzyme
involved in the metabolism of carcinogens. Conse-
quently, numerous studies have investigated the expres-
sion patterns of CYP1A1 in extrahepatic tissues, which arePage 8 of 17
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lung. CYP1A1 has been detected in lung microsomes from
human subjects by Western immunoblotting, although
the expression was rather weak [71], while EROD activity
assays demonstrated active CYP1A1 (range 7–31 nmol/
mg/protein/min). This finding has been supported by
similar results from different research groups. CYP1A1
mRNA was detected in lung specimens from 27 subjects
by semi-quantitative RTPCR in the presence and absence
of prototypical and atypical inducers, such as TCDD and
pyridine, nicotine and omeprazole respectively [72]. A
previous study from the same research group reported on
the expression of CYP1A1 to mRNA, the protein and activ-
ity levels for some lung specimens, even though consider-
able variability was noticed in the levels of proteins and
transcripts [73]. CYP1A1 expression has further been
reported in 40 out of 107 human lung adenocarcinomas
and 21 out of 57 mixed bronchioalveolar carcinomas by
immunohistochemistry, whereas the expression of both
AhR and CYP1A1 was associated with smoking in lung
adenocarcinoma patients [74]. Tobacco smoking was
shown to be associated with CYP1A1 methylation in the
lung in another study, as lung samples from active smok-
ers which lack methylation of the CYP1A1 promoter
exhibited slightly higher pulmonary EROD activity, in the
regression models for age and daily consumption of
tobacco [75]. In addition, the expression of CYP1A1 and
AhR in small-cell lung carcinoma has been proposed as a
putative diagnostic marker and has also been correlated
with a history of cigarette smoking [76,77].
Based on these observations the exact function of CYP1A1
in extrahepatic tissues, such as the lung remains
unknown. Most studies that have examined the CYP1A1
expression profile in lung tissues have largely been influ-
enced by the paradoxical induction of the enzyme by envi-
ronmental chemicals, as a result of continuous exposure
to them. Other studies have attempted to explore a differ-
ential overexpression of CYP1A1 between tumor and nor-
mal cells, which can potentially add to the various
applications of the enzyme in cancer pathology and treat-
ment. Murray and colleagues have performed a series of
studies on the expression of the extrahepatic CYPs in var-
ious tissues from normal and cancerous origin, in the
absence of an inducer. The most significant finding of this
research group was the identification of the enzyme
CYP1B1 as a tumor marker, since the CYP1B1 protein was
detected in a vast range of tumor tissues, irrespective of
their oncogenic origin. Notably, however, the protein was
absent in the corresponding normal samples [78]. Murray
et al. have drawn similar associations regarding the differ-
ential overexpression of CYP1A1 in non-cancerous and
cancerous tissues although this CYP1 isoform was shown
to be present in a smaller range of tumors, compared to
CYP1B1. CYP1A1 is present to a greater extent in malig-
nant than in normal breast tissues, as determined by
mRNA level expression [79-81], whereas in neoplastic
mammary tissue oestradiol C-2 hydroxylase activity,
which is a marker of CYP1A1 activity, was observed [82].
CYP1A enzymes were also present in a small percentage of
non-neoplastic samples of oesophageal tissue, whereas in
oesophageal carcinomas the enzymes were expressed in at
least 60% of the samples [83]. Cytochromes P450 CYP1A
were further detected in 68% of the urinary bladder
tumors and their expression correlated with bladder
tumor grade [84]. Such findings add to the well-estab-
lished carcinogen-activating role of CYP1A1, since a
higher expression of the enzyme would be expected in
pre-malignant or malignant tissues due to the continuous
exposure and subsequent metabolism by PAHs and
related compounds.
Several studies have investigated the expression of
CYP1A1 in human placenta cells because of the substrate
specificity towards oestradiol and the potential carcino-
genic and harmful effects to the developing fetus. Xenobi-
otic metabolism in the placenta is thought to be critical,
particularly in the first trimester of pregnancy, whereas the
activity of CYP-metabolizing enzymes declines in the sec-
ond and third trimesters [85,86]. CYP1A1 has been found
to be actively present in human placenta obtained from
smokers, whereas in microsomes prepared from non-
smokers the activity was considerably lower [87]. In the
BeWo, the human choriocarcinoma cell line, CYP1A1,
was readily induced as reported by Western immunoblot-
ting and the EROD assay in the presence of PAHs (3-meth-
ylcholanthrene, 1,2-benzanthracene, α-napthoflavone),
while in the absence of any inducer activity was minimal
[88]. CYP1A1 activity in placenta tissues from subjects
who were smokers has been well supported by other stud-
ies [89,90]. Elevated CYP1A1 activity in such tissues may
contribute to several adverse birth outcomes, such as
growth retardation and premature birth.
Further extrahepatic tissues in which CYP1A1 has been
shown to be present include the intestine and the skin. It
is becoming increasingly accepted that intestinal metabo-
lism is a significant contributor to the hepatic metabolism
of certain classes of xenobiotics [91]. CYP1A1 mRNA has
been detected at low levels in the duodenum and jejunum
of some donors [87,92,93]. Similar associations between
smoking and CYP1A1 expression in the human duode-
num were observed, compared to other extrahepatic tis-
sues, i.e. CYP1A1 protein and activity were elevated in
smokers [87]. CYP1A1 mRNA expression has also been
detected in the skin, as well as in normal human keratino-
cytes. Finally recent studies have demonstrated the upreg-
ulation of CYP1A1 mRNA, protein and enzymatic activity
in HUVECs, as well as human endothelial cells under
shear stress, suggesting that an increased expressionPage 9 of 17
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[94,95]. Constitutive CYP1A1 mRNA protein was also
noted by immunostaining in endothelial cells [95].
It is generally accepted in the literature that as a result of
exposure to environmental compounds with pro-muta-
genic/pro-carcinogenic activity, the basal expression of
CYP1A1 in extrahepatic tissues is linked to a great extent
to the mechanism of chemical carcinogenesis. Neverthe-
less, further studies are required, in order to provide sub-
stantial insight to the exact mechanisms of CYP1A1
regulation in extrahepatic tissues.
CYP1A1 polymorphisms
Several mutations in CYP1A1 have been found, corre-
sponding to 15 different allelic variants http://
www.imm.ki.se/CYPalleles. The first of these polymor-
phisms, CYP1A1* involves a thymidine to cytosine substi-
tution at position 3801 of the 3' non-coding region
downstream of the polyadenylation site [96]. Should the
nucleotide change be found to be in the same position at
the 3' non-coding region only, it is denoted CYP1A1*2B
[97]. The second most commonly encountered CYP1A1
polymorphism involves an Adenine to Guanine base tran-
sition at position 2455A→G of codon 462 at exon 7, and
is also known as CYP1A1*2B or Ile462Val due to the
amino acid change [97]. If the amino acid is located in the
haem-binding region, the corresponding variant is
referred to as CYP1A1*2C [98].
Conventional theory regarding the effect of polymor-
phisms on CYP1A1 suggests that the variants affect the
function of the enzyme by altering the level of gene
expression or the mRNA stability, although the results in
the literature appear to be contradictory [98]. For exam-
ple, the Ile462Val polymorphism was found to confer
increased levels of induced or basal CYP1A1 mRNA as the
number of Val variants increased in one study, whereas in
purified Escherichia Coli, no difference in the metabolism
of benzo[a]pyrene between the Ile and Val variants was
noted [99,100]. Similarly, a high activity or lack of corre-
lation has been suggested with the 3801TC and Ile462Val
polymorphisms regarding the activity of mutant enzymes
in lymphocytes [101-104].
Generally, evidence regarding the association of genetic
polymorphisms of CYP1A1 with cancer occurrence is con-
flicting, as some studies have concluded that there is
increased susceptibility to cancer in the presence of poly-
morphic variants, whereas others have reported no rela-
tionship between the two [105,106]. Although a large
body of experimental results points towards a positive
association of CYP1A1 genetic polymorphisms and cancer
occurrence, further investigation is required for such find-
ings to be extrapolated successfully to human popula-
tions.
Intracellular localization of CYP1A1
Cytochrome P450s are generally located in the endoplas-
mic reticulum and require the coenzyme NADPH reduct-
ase which catalyzes the two electron reduction of
molecular O2 to H2O for their enzymatic activity. Early
investigations showed that in addition to the ER localiza-
tion, CYP1A1 is present in the mitochondria of liver tissue
from rats pretreated with β-napthoflavone, a CYP1
inducer [107,108]. Subsequent studies revealed that
CYP1A1 is present in both endoplasmic reticulum and
mitochondrial inner membrane, depending on the tissue,
animal age and inducer pretreatment. The enzyme is tar-
geted to the mitochondria by proteolysis of cryptic MT-
targeting signals, which remove a certain number of
amino acids from the NH2 terminus, thus producing two
alternative truncated isoforms of mitochondrial CYP1A1
(mt1A1). Mouse mt-Cyp1a1 shows distinct substrate spe-
cificity from the ER-associated form and metabolizes
erythromycin as well as a number of psychotropic drugs,
probably due to the presence of ferredoxin-1-reductase
(FDX1) as a coenzyme, in place of the NADPH reductase
found in the microsomal CYP1A1 [109]. A previous study
supports the notion that it is the microsomal (mc-
Cyp1a1) rather than the mitochondrial form of the
enzyme (mtp-Cyp1a1) which contributes to B[a]P detox-
ication, by experiments in three knock-in C57B4/6J mice
lines [110]. Cyp1a1(-/-) and Cyp1a1(mtp/mtp) mice
showed striking toxicity following 18 days of daily oral
B[a]P treatment, compared to wild-type and Cyp1a1 (mc/
mc) mice, which were completely protected [110].
CYP1A1 contribution to cancer prevention
The most significant line of evidence which contradicts
the previously proposed carcinogen-activating role of
CYP1A1, comes from Nebert and the generation of
Cyp1a1 (-/-) knockout mice. C57BL/6J mice lacking the
Cyp1a1 gene died within 30 days of 125 mg/kg/day oral
B[a]P treatment, whereas Cyp1a1 (+/+) mice survived
with no overt signs of toxicity [111]. In addition, the clear-
ance rate of B[a]P in the Cyp1a1 (-/-) strain was 4 times
slower as compared to Cyp1a1 (+/+) mice, while further
pharmacokinetic experiments using TCDD and B[a]P sug-
gested that clearance was almost exclusively dependent on
inducible CYP1A1 and no other TCDD-B[a]P-inducible-
metabolizing phase I enzyme [111]. B[a]P treatment had
toxic effects in the immune system of Cyp1a1 (-/-) mice,
while chemical depression of the bone marrow was noted
at a dose as low as 1.25 mg/kg/day [111]. The data showed
for the first time that this enzyme is more important in
detoxication of B[a]P in the liver and intestine, rather than
metabolic activation to its ultimate carcinogenic conver-
sion products. From this initial observation the same
group published a series of studies where Cyp1a1/1b1 (-/
-) double knockout and Cyp1a1/1a2/1b1 (-/-) triple
knockout mouse lines were generated from straightfor-
ward genetic crosses of Cyp1a1 (-/-), Cyp1b1 (-/-) andPage 10 of 17
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metabolize B[a]P. Compared with Cyp (+/+) wild-type
mice, the Cyp1a1/1b1 (-/-) mice showed ~75 fold higher
amounts of blood B[a]P after 5 days of feeding, demon-
strating that the total body burden of B[a]P is independ-
ent of target organ damage [112]. The phenotype of this
transgenic line revealed decreased spleen and thymus
weights and increased liver weights [112]. Despite this
discrepancy Cyp1a1/1b1 (-/-) and Cyp1b1 (-/-) mice dis-
played no significant difference in cellularity of the bone
marrow following B[a]P treatment as opposed to Cyp1a1
(-/-) mice. B[a]P-DNA adduct patterns in Cyp1a1/1b1 (-/
-) doubleknockout mice were proportionate to the rela-
tive degree of immunotoxicity and followed the order
Cyp1a1 (-/-) >>>> Cyp1a1/1b1 (-/-) > Cyp (+/+) [112].
Thus although CYP1A1 contributes to detoxication,
CYP1B1 expression in spleen and marrow is responsible
for the metabolic activation of B[a]P, causing immune
damage in mice which lack the Cyp1b1 gene [112]. The
same "rescued" response following oral B[a]P treatment
was observed in the triple knockout Cyp1a1/1a2/1b1 (-/-
) mouse line, i.e. the absence of CYP1B1 in immune tis-
sues is sufficient to avoid substantial bone marrow
depression [113]. The phenotypic abnormalities of the tri-
ple knockout mouse line, which included a greater risk of
embryolethality before gestational day 11, hermaphro-
ditism and formation of cystic ovaries, were attributed to
alterations in the production catabolism and/or forma-
tion of eicosanoids, bioactive mediators derived from ara-
chidonic acid via ω-6 fatty acid synthesis and from
eicosapentanoic acid via ω-3 fatty acids, which are
involved in inflammation, innate immunity, angiogenesis
and various other developmental processes [113]. Given
that human and mouse CYP1A1 and CYP1A2 orthologs
differ in the rates of metabolism of xenobiotics, Nebert
and colleagues proceeded in the generation of a "human-
ized" hCYP1A1_CYP1A2_Cyp1a1/1a2 (-/-) mouse line.
The successful insertion of both human CYP1A in place of
the mouse Cyp1a genes returns the phenotype of the
Cyp1a1/1a2 (-/-) double knockout line back to approxi-
mately that of the wild type, whereas the human CYP1A1
enzyme partially rescues the animal from oral B[a]P-
induced immunosuppresion [114]. Although the
hCYP1A1_CYP1A2_Cyp1a1/1a2 (-/-) mouse line offers
unique opportunities for direct human CYP1A1 in vivo
carcinogen metabolism studies caution should be taken as
to whether results can successfully be extrapolated to
human populations. For example, it is possible that the
mouse relies more on the small intestine than the liver for
B[a]P metabolism, whereas the opposite may be true for
humans. Such organ differences regarding the metabo-
lism of xenobiotics between the two species should be
taken into account and further experiments are required
to provide a full understanding of the use of this trans-
genic model in environmental toxicology and cancer
pharmacology.
As mentioned earlier CYP1A1 enzyme expression is
linked with important physiological and cell growth regu-
latory processes, through the involvement of AhR with
multiple pathways other than the xenobiotic activating
pathway. Recent experiments performed in lung tissue
from mice which were AhR-null, suggest that AhR and
CYP1A1 are subjected to an autoregulatory feedback loop,
thus supporting the presence of an as yet unidentified
endogenous ligand. Since the transient transfection of CV-
1 cells with a CYP1A1 and an AhR expression vector led to
a markedly reduced DRE-driven luciferase reporter activ-
ity, the authors of this study proposed that CYP1A1 in
turn metabolizes the putative endogenous ligand, result-
ing in its inactivation and consequently in the attenuation
of the AhR pathway [115]. As well as unraveling the pre-
cise contribution of this enigmatic orphan receptor in nor-
mal cellular metabolism, such evidence can add to the
significance of excessive activation of AhR by xenobiotics
and the identification of new molecular targets for thera-
peutic drug development [115].
Regarding the pharmacological aspects of CYP1A1 xeno-
biotic-mediated metabolism accumulated evidence has
corroborated the recent knockout mice findings, suggest-
ing a cancer-protecting role of the enzyme by paradoxical
activation of small synthetic molecules, as well as natural
products present in the diet, to more antiproliferative
agents. The synthetic compound Phortress or 2-(4-
Amino-3-methylphenyl) benzothiazole is a CYP1A1-acti-
vated prodrug with potent in vivo activity in breast tumor
xenografts [116]. Of note is that the natural AhR ligand
indirubin and Phortress possess a very similar structure
based on a benzimidazole ring. Nevertheless, this com-
pound was not initially designed for the purpose of
CYP1A1 induction. Initial studies suggested it had prom-
ising antitumour effects; however, its exact mechanism of
action was elucidated in subsequent studies. Phortress,
which entered early Phase I clinical trials in 2004, induces
CYP1A1 in breast cancer sensitive cell lines, such as MCF-
7, T-47D and IGROV (IC50 < 10 nM) and is further metab-
olized by CYP1A1 to reactive electrophillic species which
results in DNA adduct formation [116-118]. This induc-
tion involves the binding of AhR to ARNT and transloca-
tion of the complex to the nucleus, as observed in the case
of benzo[a]pyrene [119]. Another chemotherapeutic
agent in this category, aminoflavone, also acts by the
induction of CYP1A1 and its subsequent activation.
Aminoflavone is active in MCF7 cell lines (IC50 = 0.1 nM)
and MCF7 xenografts [120]. Again, AhR is required for
CYP1A1 induction, rendering this compound 4,500-fold
less active in MCF7 AhR-null mutant cells. Induced
CYP1A1, in turn, converts aminoflavone to metabolites
that form DNA protein crosslinks and cause DNA double-
strand breaks, thereby inhibiting DNA synthesis in the S
phase [121]. The molecular pathway of CYP1A1-mediated
aminoflavone activation is shown in Figure 4A.Page 11 of 17
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which belong to the flavonoid subclass, have recently
been identified as CYP1A1 substrates. The flavonoid
eupatorin found in medicinal plants in South East Asia
and South America, was recently shown to be converted to
the structurally similar flavone cirsiliol, by an aromatic
demethylation reaction catalysed by the enzymes CYP1A1
and CYP1B1 [122]. Eupatorin strongly inhibits the in vitro
proliferation of MDA-MB-468 human breast cancer cells
that express CYP1A1, but it is inactive in normal breast
MCF-10A cells, devoid of any CYP1A1 activity [122]. The
isoflavone daidzein, a component of soy beans, is a sub-
strate for CYP1A1 as demonstrated by in vitro enzyme and
cell-based assays [123]. Aromatic hydroxylation of daid-
zein at the 3' position enhances the antiproliferative activ-
ity of the compound in MCF-7 cells [123]. Similarly, the
flavone diosmetin, present in olive leaves, is activated to
the flavone luteolin, mainly by CYP1A1. CYP1A1-medi-
ated metabolism of diosmetin in MDA-MB-468 and
TCDD-induced MCF-7 cells increases its biological activ-
ity [124,125]. A recent study has reported that CYP1A1
has the highest rate of metabolism, compared to the
hepatic CYPs 1A2, 3A4, 2C9 and 2D6, of fully methylated
anticancer flavonoids such as tangeretin, a high constitu-
ent of orange peel [126]. The flavonols galangin and
kaempferide have also been reported to be substrates of
The two different models for the contribution of CYP1A1 to chemopreventionFigure 4
The two different models for the contribution of CYP1A1 to chemoprevention. (A) Molecular mechanism of 
aminoflavone AhR-induced CYP1A1 activation. It must be stressed that this mechanism of action is also likely to apply for cer-
tain dietary natural products, such as the flavonoid diosmetin, which induces CYP1A1 expression and is a substrate of the same 
enzyme [129,124,125]. (B) Chemopreventative action of natural products, such as the stilbene resveratrol, is based on the inhi-
bition of benzo[a]pyrene binding to AhR, the binding of the AhR-ARNT-benzo[a]pyrene complex to xenobiotic response ele-
ments (XREs), and the inhibition of the formation of CYP1A1-mediated carcinogenic reactive intermediates, notably 
benzo[a]pyrene-7,8-diol-9,10-epoxide.Page 12 of 17
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galangin is hydroxylated at position 4' to produce kaemp-
ferol another anticancer flavonoid found in black and
green tea [128]. Of note is that the CYP1A1-catalyzed
metabolism of dietary anticancer flavonoids produces
compounds that also possess strong cancer preventative
activity.
Certain flavonoids are capable of inducing CYP1A1 activ-
ity via the AhR in cancer cell line models [129-131]. The
hypothesis that has been established by such findings fol-
lows the so-called blocking type of chemopreventative
agent. Dietary constituents suppress cancer progression by
inhibiting the CYP1A1-catalyzed metabolic activation
and the CYP1A1 enzyme induction of carcinogens. The
second occurs either by the blockage of AhR binding to
the inducer or by the prevention of AhR-ARNT binding to
XREs (Figure 4B) [132]. Although most of the compounds
examined possess inhibitory activity against CYP1A1, the
model does not adequately explain why CYP1A1 is
induced and further inhibited. As the AhR-mediated
induction of CYP1A1 is noted for a large amount of phy-
tochemicals present in the diet, it can be assumed that the
subsequent metabolism of these compounds is the end
stage of this process, as has been noted for the procarcino-
gen benzo[a]pyrene [133]. More importantly, in in vitro or
in vivo models where cell lines with a malignant pheno-
type are used, the inhibition of CYP1A1 ought not to alter
the tumorigenic state of the cells, since they have already
lost the ability to control their growth. In this sense, the
action of dietary flavonoids and phytochemicals as
CYP1A1 inhibitors is subject to further consideration. The
induction of CYP1A1 in cancer cells by dietary com-
pounds and their subsequent metabolism to more active
agents is an alternative model that can explain the cancer
preventative properties of these compounds in pharmaco-
logically relevant concentrations [134]. In addition, many
compounds that appear as CYP1A1 competitive inhibi-
tors may well be CYP1A1 substrates.
Conclusion
P450s are believed to have existed since the beginning of
life over 3.5 billion years ago, but the P450s responsible
for foreign compound metabolism appear to have arisen
about 400 to 500 million years ago. It is believed that
these enzymes were needed to metabolise and detoxify
chemicals found in plants [135]. In the plant-animal
"warfare" hypothesis, plants produce toxins to kill preda-
tors and animals evolve P450s to detoxify these toxins. As
this process continues over millions of years new catalytic
activities of P450s will develop. However, in the field of
chemical carcinogenesis it is difficult to establish a clear
relationship in which both the P450s and other foreign
compound metabolizing enzymes would evolve for a
beneficial purpose.
Although the majority of the studies have focused on the
carcinogenic action of CYP1A1, it is recently becoming
clear that this enzyme plays important roles in detoxica-
tion and chemoprevention, thus opposing the initially
established concept, regarding its function in tumor pro-
gression. Moreover, extensive work on the molecular
events governing the transcriptional activation of the
CYP1A1 gene through the aryl hydrocarbon receptor has
revealed the interplay of AhR with various cell signaling
pathways, important in normal cell growth, homeostasis
and development. The cross-talk of AhR with different sig-
nal transduction pathways is apparent. However, the pre-
cise mechanisms by which AhR ligands elicit toxic
responses that may contribute to carcinogenesis still
remain unclear. It was previously noted that this may be
partially due to the majority of the studies coming from
cancer-derived cell lines that have impaired cell cycle reg-
ulation and hence do not possess the full detoxication
battery [34]. Studies in non-transformed cells or extrahe-
patic tissues have been proposed as better models of
choice [34]. Utilization of these systems can unravel the
exact mechanisms which regulate the expression of
CYP1A1 in extrahepatic tissues, and offer insight into the
contribution of the latter in cancer progression or preven-
tion.
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